依給藥途徑、藥物類別、通路和最終用戶分類的酒精使用障礙治療市場－2026-2032年全球預測

預計到 2025 年，酒精使用障礙治療市場價值將達到 11 億美元，到 2026 年將成長到 12 億美元，到 2032 年將達到 21.7 億美元，複合年成長率為 10.11%。

關鍵市場統計數據
基準年 2025	11億美元
預計年份：2026年	12億美元
預測年份 2032	21.7億美元
複合年成長率 (%)	10.11%

策略實施以不斷發展的臨床證據、製劑技術、支付方優先事項和實際差異為框架，這些因素共同塑造了酒精使用障礙的治療方案。

酒精使用障礙的治療正經歷持續的變革時期，這主要受不斷發展的臨床證據、新型製劑技術以及支付者和監管機構優先事項轉變的推動。本文概述了現代治療格局，重點在於闡述了不同劑型和藥物類別的治療方案如何競爭臨床應用，以及系統層面的壓力如何優先考慮安全性、依從性和實際療效。本文也著重介紹了不同給藥平台（注射劑與口服片劑）之間的實際差異及其對臨床工作流程、患者依從性模式和供應鏈的影響，從而為上述變革提供了背景資訊。

製劑創新、可操作證據的產生、監管審查以及支付方的價值需求如何重塑治療方法的採納和商業策略

近年來，臨床研發、製劑科學和醫療保健系統行為的變革性變化正在重新定義酒精使用疾患治療的評估和應用方式。緩釋技術和注射的進步正在重塑關於依從性和長期復發預防的臨床討論，而口服緩釋製劑的逐步改進則為偏好非侵入性治療的患者提供了更多選擇。同時，真實世界證據的產生和實用性臨床試驗正在影響處方實踐，它們不僅在對照試驗環境中，而且在日常臨床實踐中也提供了療效比較數據。

2025 年關稅環境及其對治療藥物採購、區域製造、供應連續性和商業性定價動態的策略影響

2025年實施的關稅和貿易措施為酒精使用障礙藥物的生產商和經銷商在採購、供應鏈設計和定價策略方面帶來了新的營運限制。新的關稅制度提高了某些進口零件和成品的相對成本，迫使生產商重新評估其採購來源，並在條件允許的情況下加快生產本地化。這些變化正在影響企業的策略優先順序，因為企業需要權衡集中式低成本生產和分散式生產之間的利弊，後者可以降低關稅風險並縮短前置作業時間。

可操作的細分分析揭示了產品供應和藥物類別特徵如何影響臨床應用、營運設計和商業性重點。

詳細的細分分析揭示了不同產品類型和藥物類別在臨床、營運和商業性影響方面的顯著差異，為產品組合和市場推廣策略提供了參考。依產品類型分類，注射療法需要肌肉注射基礎設施，在某些情況下還需要靜脈輸注，這影響了其在住院戒毒病房和專科診所的應用。另一方面，口服藥片的依從性動態取決於其採用的是緩釋技術還是速釋技術。這些給藥方式的差異不僅影響臨床醫師的偏好和病患選擇，也影響物流、某些注射所需的低溫運輸以及安全給藥的訓練要求。

區域指導方針旨在協調監管差異、支付方成熟度和臨床服務規範，從而最佳化全球醫療保健系統的可近性、報銷和應用。

區域趨勢對監管路徑、支付方框架和採納模式有著顯著影響，從而在美洲、歐洲、中東和非洲以及亞太地區形成了各自獨特的戰略要務。在美洲，整合的醫療服務體系和與私人支付方強大的談判能力為快速採納基於價值的合約和循證藥物配方創造了機會；然而，都市區和非洲的監管環境則呈現出多樣性，各國不同的法規環境決策和國家處方箋流程可能會加速或延緩藥物進入市場，此外，定價和衛生經濟學的文件要求也十分複雜。

企業策略、生產夥伴關係和證據產生三者結合，決定了治療藥物供應和市場進入的競爭優勢。

公司層面的趨勢持續影響著創新軌跡和競爭定位，領導企業正尋求透過投資差異化給藥技術、進行實證研究和相關人員來鞏固其在治療領域的主導。生物製藥公司與合約研發生產機構（CDMO）之間的策略聯盟正在推動緩釋注射劑和緩釋口服製劑平台的快速規模化生產，而與學術機構和醫療系統的合作則正在產生真實世界證據，為與支付方的談判和指南的採納提供依據。同時，規模較小的專業公司和新興生物技術公司正專注於細分市場定位，開發標靶製劑，並尋求現有分子的適應症拓展，以填補尚未滿足的臨床需求。

實際的優先建議，整合了配方選擇、證據產生、加強供應鏈和支付方合作，以促進產品應用並保持競爭優勢。

產業領導者應優先考慮一系列切實可行的舉措，以協調臨床、營運和商業性需求，加速合理應用，並保持競爭優勢。首先，應投資於符合預期臨床應用情境的製劑選擇和給藥系統，確保肌肉注射、靜脈輸注和口服緩釋/速釋片劑的選擇能反映實際給藥方案和病患偏好。其次，應將可靠的真實世界證據項目與務實的試驗設計相結合，以展示能夠引起支付方和臨床醫生共鳴的療效比較、依從性優勢和醫療資源利用結果。

結合有針對性的相關人員訪談、二手文獻綜述和情境分析，採用嚴謹的混合方法，為決策者提供可複製、可操作的見解。

本研究結合了對臨床領導者、支付者和供應鏈專家的定性訪談，以及對同行評審文獻、監管指南和公共趨勢的二次分析，以確保對治療格局形成多方面的觀點。主要研究包括針對注射劑與口服療法的臨床促進因素、肌肉注射和靜脈輸注環境的操作限制以及支付方對療效和成本控制的期望等問題的結構化訪談。二次資訊用於分析不同藥物類別（Acamprosate、Baclofen、Disulfiram崙、納曲酮（長效注射劑和口服劑）和托吡酯）的安全訊號、藥理特性和歷史應用模式。

簡潔扼要、全面全面的分析，重點在於闡述製劑創新、藥物類別特徵、支付方趨勢和供應彈性等因素之間的相互作用，為策略決策提供基礎。

總而言之，酒精使用障礙的治療格局正在發生變化，這需要臨床、營運和商業性方面的協調應對。製劑和給藥方式的進步為提高患者依從性和長期治療效果提供了切實的機會，但也帶來了必須積極應對的物流和支付方相關複雜問題。不同藥物類別的特性進一步增加了決策的複雜性。從用於維持治療的藥物到需要監督給藥的藥物，每種治療方案都有其獨特的推廣促進因素和證據要求。

目錄

第1章：序言

第2章調查方法

• 研究設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查前提
• 調查限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 市場進入策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會地圖
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依給藥途徑分類的酒精使用障礙治療市場

• 注射
  • 注射（肌肉注射）
  • 皮下注射
• 口服錠劑

9. 依藥物類別分類的酒精使用疾患治療市場

• Acamprosate
• Baclofen
• Disulfiram
• 納曲酮
• 托吡酯

10. 按分銷管道分類的酒精使用障礙治療市場

• 線上
• 離線

第11章 酒精使用疾患治療藥物市場（依最終使用者分類）

• 醫院
• 研究所
• 成癮診所

12. 各地區酒精使用疾患治療藥物市場

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第13章 酒精使用疾患治療藥物市場（依類別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各國酒精使用疾患治療藥物市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

15. 美國酒精使用疾患治療藥物市場

第16章：中國酒精使用疾患治療藥物市場

第17章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Alkermes
• Ambica Pharma
• Amigoz Lifesciences
• Care Formulation Labs Private Limited
• Consern Pharma Limited
• Dhritee Impex
• Eisai Pharmaceuticals India Pvt Ltd
• Intas Pharmaceuticals Ltd.
• Johnlee Pharmaceuticals Pvt. Ltd.
• Lifegenix（Div. of Lifecare Neuro Products Ltd.）
• Mallinckrodt Pharmaceuticals
• Marshall Healthcare
• Odyssey Pharmaceuticals
• Rusan Pharma
• Salvavidas Pharmaceutical Pvt. Ltd.
• Sanofi SA
• Schwitz Biotech
• Sun Pharmaceutical Industries Ltd.
• Taj Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.

The Medications for Alcohol Use Disorder Market was valued at USD 1.10 billion in 2025 and is projected to grow to USD 1.20 billion in 2026, with a CAGR of 10.11%, reaching USD 2.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.10 billion
Estimated Year [2026]	USD 1.20 billion
Forecast Year [2032]	USD 2.17 billion
CAGR (%)	10.11%

A strategic introduction framing evolving clinical evidence, formulation technologies, payer priorities, and practical distinctions shaping treatment choices for alcohol use disorder

The treatment of alcohol use disorder is undergoing a sustained period of change driven by evolving clinical evidence, new formulation technologies, and shifting payer and regulatory priorities. This introduction frames the contemporary landscape by highlighting how therapeutic options across delivery formats and drug classes are competing for clinical adoption while system-level pressures prioritize safety, adherence, and real-world effectiveness. It sets the stage by clarifying the practical distinctions between delivery platforms-injectables versus oral tablets-and how those distinctions influence clinical workflows, patient adherence patterns, and supply chain considerations.

Furthermore, the introduction unpacks how an expanded therapeutic toolkit now includes multiple pharmacological classes with different mechanisms of action and administration requirements, prompting clinicians and health systems to adopt more nuanced treatment pathways. Given this complexity, stakeholders increasingly seek evidence that aligns formulation attributes, such as extended release injectables or immediate release oral tablets, with outcomes like retention in treatment and reductions in heavy drinking days. This context underscores the imperative for cross-functional strategies that account for clinical efficacy, administration modality, and payer acceptance to accelerate appropriate uptake and improve patient outcomes.

How innovations in formulation, pragmatic evidence generation, regulatory scrutiny, and payer value demands are reshaping therapeutic adoption and commercial strategy

Recent transformative shifts across clinical development, formulation science, and health system behavior are redefining how medications for alcohol use disorder are evaluated and adopted. Advances in extended release technologies and depot injectables have reoriented clinical conversations about adherence and long-term relapse prevention, while incremental improvements in oral extended release formulations have strengthened options for patients who prefer noninvasive therapies. At the same time, real-world evidence generation and pragmatic trials are influencing prescribing practices by providing data on comparative effectiveness in routine care settings rather than solely in controlled trials.

Concurrently, regulatory pathways and post-marketing surveillance have tightened expectations for safety monitoring and patient-reported outcomes, which is steering manufacturers toward robust pharmacovigilance frameworks and label expansions predicated on pragmatic endpoints. Payers and integrated delivery networks are increasingly focused on value-based contracting and outcomes-linked reimbursement, prompting manufacturers to demonstrate meaningful improvements in adherence, reductions in health-care utilization, and sustained abstinence or reduced heavy drinking. Taken together, these changes are prompting a reconfiguration of commercial strategies, with manufacturers investing in differentiated delivery formats, evidence generation partnerships, and stakeholder engagement to secure formulary placement and clinician buy-in.

The 2025 tariff environment and its strategic implications for sourcing, regional manufacturing, supply continuity, and commercial pricing dynamics across therapeutic formulations

The imposition of tariffs and trade measures in 2025 has introduced new operational constraints that reverberate across procurement, supply-chain design, and pricing strategy for manufacturers and distributors of medications for alcohol use disorder. Emerging tariff regimes have raised the relative cost of certain imported components and finished formulations, prompting manufacturers to reassess sourcing decisions and to accelerate regional manufacturing localization where feasible. These shifts are influencing strategic prioritization, as companies evaluate the trade-offs between centralized, low-cost production and decentralized manufacturing that mitigates tariff exposure and shortens lead times.

In response, supply-chain teams have increased focus on nearshoring, inventory buffering, and multi-sourcing critical active pharmaceutical ingredients and finished dose forms for both injectable platforms and oral tablets. These operational adjustments aim to preserve continuity of supply for intramuscular injection and intravenous infusion products as well as for extended release and immediate release oral formulations. Additionally, commercial teams must recalibrate pricing and contracting approaches to maintain market access amid added cost pressures while preserving affordability for patients and payers. Ultimately, the tariff environment has accelerated strategic planning cycles, compelling stakeholders to integrate trade policy scenarios into clinical development and commercialization roadmaps.

Actionable segmentation insights revealing how product delivery formats and distinct drug-class characteristics drive clinical adoption, operational design, and commercial focus

Deep segmentation analysis reveals meaningful differences in clinical, operational, and commercial implications across product types and drug classes that should inform portfolio and go-to-market decisions. By product type, injectable therapies require infrastructure for intramuscular injection and, in some settings, intravenous infusion, which influences adoption in inpatient detoxification units and specialized clinics, while oral tablets present differing adherence dynamics depending on whether they utilize extended release or immediate release technologies. These modality distinctions affect not only clinician preference and patient selection but also logistics, cold-chain needs for certain injectables, and training requirements for safe administration.

By drug class, therapeutic choice carries implications for mechanism-driven efficacy and tolerability profiles that shape prescriber behavior and patient trajectories. Acamprosate and baclofen are often positioned for maintenance strategies with attention to long-term tolerability, whereas disulfiram continues to occupy a niche where supervised administration and behavioral supports are central to effectiveness. Naltrexone presents a bifurcated pathway, as both extended release injectable formulations and oral tablets are in clinical use, each offering trade-offs between adherence assurance and ease of discontinuation or dose adjustment. Topiramate, used off-label in many jurisdictions, requires careful titration and monitoring for cognitive side effects. Taken together, these segmentation dimensions suggest that successful commercialization requires synchronized strategies that align formulation attributes with drug-class specific clinical profiles and the operational realities of intended care settings.

A regional playbook that aligns regulatory variation, payer maturity, and clinical delivery norms to optimize access, reimbursement, and adoption across global health systems

Regional dynamics exert pronounced influence on regulatory pathways, payer frameworks, and adoption patterns, producing distinct strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated delivery systems and a high degree of private payer negotiation create opportunities for value-based contracting and rapid uptake of evidence-backed formulations, although access disparities persist between urban centers and rural areas. In contrast, Europe, Middle East & Africa features heterogeneous regulatory environments where country-level reimbursement decisions and national formulary processes can either accelerate or slow market entry, requiring nuanced pricing and health-economic dossiers.

Meanwhile, Asia-Pacific presents a mix of rapidly expanding health-care infrastructure and diverse payer maturity, which supports multiple commercialization models from hospital-based specialty distribution for injectables to pharmacy-driven supply for oral tablets. Each region also carries distinct clinical practice patterns; for example, some countries prioritize supervised administration programs that may favor depot injectables, while others emphasize outpatient management where oral immediate release or extended release tablets are more practical. Consequently, regional strategies must reconcile regulatory timing, procurement logistics, and clinical delivery norms to optimize access, reimbursement, and long-term uptake across disparate health systems.

How corporate strategy, manufacturing partnerships, and evidence generation are converging to determine competitive advantage in therapeutic delivery and market access

Company-level dynamics continue to shape innovation trajectories and competitive positioning, with leaders investing in differentiated delivery technologies, evidence generation, and stakeholder engagement to secure therapeutic leadership. Strategic partnerships between biopharma companies and contract development and manufacturing organizations are enabling rapid scale-up of depot injectables and extended release oral platforms, while alliances with academic centers and health systems are producing real-world evidence that informs payer negotiations and guideline inclusion. At the same time, smaller specialty firms and emerging biotech companies focus on niche positioning, developing targeted formulations or pursuing label expansions for established molecules to capture unmet clinical segments.

Commercially, firms that integrate lifecycle planning-from early formulation selection to post-marketing safety programs and value demonstration-are better positioned to navigate complex reimbursement landscapes. Investment in clinician education, nurse-led administration pathways, and digital adherence tools can differentiate products in crowded therapeutic classes. Moreover, companies that proactively address manufacturing resilience and tariff-related supply-chain risks secure a competitive advantage by ensuring consistent product availability, which translates directly into prescriber confidence and patient continuity of care.

Practical and prioritized recommendations that synchronize formulation selection, evidence generation, supply resilience, and payer engagement to accelerate adoption and sustain competitive differentiation

Industry leaders should prioritize a set of actionable initiatives that align clinical, operational, and commercial imperatives to accelerate appropriate use and sustain competitive advantage. First, invest in formulation choices and delivery systems that match intended care settings, ensuring that choices between intramuscular injection, intravenous infusion, and oral extended or immediate release tablets reflect real-world administration capacity and patient preferences. Next, integrate robust real-world evidence programs and pragmatic trial designs to demonstrate comparative effectiveness, adherence benefits, and health-care utilization outcomes that resonate with payers and clinicians.

Simultaneously, reassess supply-chain architectures to mitigate tariff exposure through multi-sourcing strategies and regional manufacturing where feasible, and enhance manufacturing transparency to support procurement negotiations. From a commercial standpoint, develop modular value propositions tailored to different drug classes, emphasizing tolerability profiles and mechanism of action where relevant. Strengthen provider education and training for safe administration of injectables and create digital tools to support adherence for oral regimens. Finally, pursue strategic payer engagements early to explore outcomes-based contracting or pilot programs that align incentives around patient-centered outcomes and long-term treatment retention.

A rigorous mixed-methods approach combining targeted stakeholder interviews, secondary literature integration, and scenario analysis to produce reproducible, actionable insights for decision-makers

This research synthesizes primary qualitative interviews with clinical leaders, payers, and supply-chain experts alongside secondary analysis of peer-reviewed literature, regulatory guidance, and public policy developments to ensure a multidimensional view of the therapeutic landscape. Primary engagement included structured interviews that probed clinical decision drivers for injectable versus oral therapies, operational constraints for intramuscular injection and intravenous infusion settings, and payer expectations for outcomes and cost containment. Secondary sources were leveraged to contextualize safety signals, pharmacology, and historical adoption patterns across drug classes including acamprosate, baclofen, disulfiram, naltrexone in both extended release injectable and oral forms, and topiramate.

Analytical techniques combined thematic qualitative synthesis with scenario planning to assess the impact of regulatory shifts and tariff environments on supply-chain and pricing strategies. Where applicable, triangulation between stakeholder interviews and published clinical evidence was used to validate practice-pattern assertions and to identify gaps requiring further primary research. The approach prioritizes transparency in assumptions and emphasizes reproducibility of findings through clear documentation of data sources, interview guides, and analytic frameworks, enabling stakeholders to adapt the insights to their unique strategic questions.

A concise synthesis highlighting the interplay of formulation innovation, drug-class nuances, payer dynamics, and supply resilience necessary to inform strategic decision-making

In summary, the treatment landscape for alcohol use disorder is evolving in ways that require coordinated clinical, operational, and commercial responses. Advances in formulation and delivery modalities create real opportunities to improve adherence and long-term outcomes, but they also introduce logistical and payer-related complexities that must be proactively managed. Drug-class specific profiles further complicate the decision environment; each therapeutic option-from agents used for maintenance strategies to medications that require supervised administration-carries distinct adoption drivers and evidence needs.

To navigate this complexity successfully, stakeholders should align formulation strategy with care-delivery realities, invest in real-world evidence to support value arguments, and strengthen supply-chain resilience in the face of trade-policy shifts. Companies that integrate these priorities into cohesive lifecycle plans and engage early with payers and clinicians will be best positioned to translate scientific advances into sustained clinical and commercial impact. This conclusion underscores the imperative for deliberate strategy, rigorous evidence generation, and operational foresight to realize the full potential of medication-based approaches to alcohol use disorder treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medications for Alcohol Use Disorder Market, by Route of Administration

• 8.1. Injectables
  • 8.1.1. Injectable Intramuscular
  • 8.1.2. Injectable Subcutaneous
• 8.2. Oral Tablets

9. Medications for Alcohol Use Disorder Market, by Drug Class

• 9.1. Acamprosate
• 9.2. Baclofen
• 9.3. Disulfiram
• 9.4. Naltrexone
• 9.5. Topiramate

10. Medications for Alcohol Use Disorder Market, by Distribution Channel

• 10.1. Online
• 10.2. Offline

11. Medications for Alcohol Use Disorder Market, by End User

• 11.1. Hospitals
• 11.2. Research Institutes
• 11.3. Addiction Clinics

12. Medications for Alcohol Use Disorder Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Medications for Alcohol Use Disorder Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Medications for Alcohol Use Disorder Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Medications for Alcohol Use Disorder Market

16. China Medications for Alcohol Use Disorder Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Alkermes
• 17.6. Ambica Pharma
• 17.7. Amigoz Lifesciences
• 17.8. Care Formulation Labs Private Limited
• 17.9. Consern Pharma Limited
• 17.10. Dhritee Impex
• 17.11. Eisai Pharmaceuticals India Pvt Ltd
• 17.12. Intas Pharmaceuticals Ltd.
• 17.13. Johnlee Pharmaceuticals Pvt. Ltd.
• 17.14. Lifegenix (Div. of Lifecare Neuro Products Ltd.)
• 17.15. Mallinckrodt Pharmaceuticals
• 17.16. Marshall Healthcare
• 17.17. Odyssey Pharmaceuticals
• 17.18. Rusan Pharma
• 17.19. Salvavidas Pharmaceutical Pvt. Ltd.
• 17.20. Sanofi S.A.
• 17.21. Schwitz Biotech
• 17.22. Sun Pharmaceutical Industries Ltd.
• 17.23. Taj Pharmaceuticals
• 17.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 56. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 62. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 64. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 67. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 68. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 69. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 70. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 71. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 80. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 81. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 82. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 83. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 84. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 85. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 86. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 88. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 89. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 90. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 91. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 92. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 94. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 95. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 96. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 97. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 99. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 100. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 101. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 102. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 103. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 104. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 105. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 107. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 108. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 109. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 110. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 111. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 113. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 114. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 115. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 116. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 117. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 119. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 120. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 121. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 122. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 123. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 125. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 126. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 127. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 128. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 129. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 131. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 132. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 133. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 134. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 136. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 137. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 138. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 139. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 140. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 141. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 142. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 143. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 144. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
• TABLE 145. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 146. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 147. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)